O'Riordan W, et al. - Researchers analyzed the data to estimate the outcome of omadacycline in candidates with acute bacterial skin and skin-structure infections. Adults were given omadacycline (100 mg given intravenously every 12 hours for two doses, then 100 mg given intravenously every 24 hours) or linezolid (600 mg given intravenously every 12 hours) randomly. They noticed the effectiveness of both the drugs similar for methicillin-susceptible and methicillin-resistant Staphylococcus aureus infections. They found adverse events in 48.3% of cases in omadacycline group and in 45.7% of those in the linezolid group. Overall, they concluded omadacycline noninferior to linezolid and also had a similar safety profile.